



Product Datasheet

Product Name	Estrogen Receptor Binding Site Associated Antigen 9 Human Recombinant
Cata No	CB500964
Source	<i>Escherichia Coli.</i>
Synonyms	EB9, PDAF, RCAS1, EBAG9, Receptor-binding cancer antigen expressed on SiSo cells, Cancer-associated surface antigen RCAS1, Estrogen receptor-binding fragment-associated gene 9 protein.

Description

EBAG9 is a type III transmembrane protein that is primarily located in the Golgi. EBAG9 is a tumor-associated antigen that is expressed at high frequency in a variety of cancers, such as advanced breast and prostate cancers. While the EBAG9 acts to inhibit the growth of receptor-binding cells and induced apoptosis of immune cells, cancer cells may evade immune surveillance. Thus immunodetection of EBAG9 expression can be a negative prognostic indicator. EBAG9 promotes progression of bladder cancer. In rheumatoid arthritis, the deficiency of EBAG9 induces CTL infiltration through failure to evade immune attack, therefore leading to apoptosis of the synovial lining cells. EBAG9 is involved in controlling exocytosis processes. EBAG9 expression plays a role in the progression of oral squamous cell carcinoma. EBAG9 plays a specific role in premature stages of breast carcinogenesis. EBAG9 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 207 amino acids (28-213) and having a molecular mass of 23.4 kDa. The EBAG9 protein is fused to 20 amino acid His-Tag at N-terminus and purified by standard chromatography techniques.

Physical Appearance

Sterile Filtered colorless solution

Purity

Greater than 90% as determined by SDS-PAGE.

Formulation

The EBAG9 protein solution contains 20mM Tris-HCl pH-8, 1mM DTT, 2mM EDTA and 10% glycerol.

Stability

EBAG9 although stable 4°C for 4 weeks, should be stored desiccated below -18°C.

For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Please prevent freeze-thaw cycles.

Sequence

GSSHHHHH SSSLVPRGSH MRSGRGRKLS
GDQITLPTTV DYSSVPKQTD VEEWTSWDED
APTSVKIEGG NGNVATQQNS LEQLEPDYFK
DMTPTIRKTQ KIVIKKREPL NFGIPDGSTG
FSSRLAATQD LPFIHQSSSEL GDLDTWQENT
NAWEEEEEDAA WQAEVLRQQ KLADREKRAA
EQQRKKMEKE AQRLMKKEQN KIGVKLS.